Amazonian biodiversity: a view of drug development for Leishmaniasis and malaria

Detalhes bibliográficos
Autor(a) principal: Calderon,Leonardo de Azevedo
Data de Publicação: 2009
Outros Autores: Silva-Jardim,Izaltina, Zuliani,Juliana Pavan, Silva,Alexandre de Almeida e, Ciancaglini,Pietro, Silva,Luiz Hildebrando Pereira da, Stábeli,Rodrigo Guerino
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Journal of the Brazilian Chemical Society (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532009000600003
Resumo: Chemotherapy is the only validated therapy for the treatment for the neglected diseases leishmaniasis and malaria. However, the emergence of drug resistance, collateral effects and long-term treatment encourage the development of new and more efficient drugs. The Amazon tropical forest includes the richest areas of biodiversity in the world, including a great number of microbes, plant and animal species that produce a source of interesting biologically active molecules. Several of these molecules, obtained from plant extracts and frog venom have leishmanicidal and plasmodicidal activity, highlighting the potential of this biodiversity for the development of new drugs. In research, modern approaches in new drug development are carried out using combinatorial chemistry, high-throughput screening, bioinformatics, molecular interaction, crystallography and dynamic studies of cellular and systemic toxicity. In Brazil, these techniques are mainly present in only a few academic groups with no efficient connection to industry. The problem associated with over-regulation for accessing the biological material in restricted areas, local populations and indigenous areas places major barriers in the path of research and development of new drugs. Thus, the association of academic research groups in Brazil, encouraged and supported by government and industry, is essential to overcome these major barriers related to the development of new products for treatment of neglected diseases from Amazonian biodiversity in future years.
id SBQ-2_57cb38ee3fd5c3e5cc579d81a96da57f
oai_identifier_str oai:scielo:S0103-50532009000600003
network_acronym_str SBQ-2
network_name_str Journal of the Brazilian Chemical Society (Online)
repository_id_str
spelling Amazonian biodiversity: a view of drug development for Leishmaniasis and malariaAmazoniabiodiversityleishmaniasisLeishmaniamalariaPlasmodiumdrug developmentChemotherapy is the only validated therapy for the treatment for the neglected diseases leishmaniasis and malaria. However, the emergence of drug resistance, collateral effects and long-term treatment encourage the development of new and more efficient drugs. The Amazon tropical forest includes the richest areas of biodiversity in the world, including a great number of microbes, plant and animal species that produce a source of interesting biologically active molecules. Several of these molecules, obtained from plant extracts and frog venom have leishmanicidal and plasmodicidal activity, highlighting the potential of this biodiversity for the development of new drugs. In research, modern approaches in new drug development are carried out using combinatorial chemistry, high-throughput screening, bioinformatics, molecular interaction, crystallography and dynamic studies of cellular and systemic toxicity. In Brazil, these techniques are mainly present in only a few academic groups with no efficient connection to industry. The problem associated with over-regulation for accessing the biological material in restricted areas, local populations and indigenous areas places major barriers in the path of research and development of new drugs. Thus, the association of academic research groups in Brazil, encouraged and supported by government and industry, is essential to overcome these major barriers related to the development of new products for treatment of neglected diseases from Amazonian biodiversity in future years.Sociedade Brasileira de Química2009-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532009000600003Journal of the Brazilian Chemical Society v.20 n.6 2009reponame:Journal of the Brazilian Chemical Society (Online)instname:Sociedade Brasileira de Química (SBQ)instacron:SBQ10.1590/S0103-50532009000600003info:eu-repo/semantics/openAccessCalderon,Leonardo de AzevedoSilva-Jardim,IzaltinaZuliani,Juliana PavanSilva,Alexandre de Almeida eCiancaglini,PietroSilva,Luiz Hildebrando Pereira daStábeli,Rodrigo Guerinoeng2009-08-04T00:00:00Zoai:scielo:S0103-50532009000600003Revistahttp://jbcs.sbq.org.brONGhttps://old.scielo.br/oai/scielo-oai.php||office@jbcs.sbq.org.br1678-47900103-5053opendoar:2009-08-04T00:00Journal of the Brazilian Chemical Society (Online) - Sociedade Brasileira de Química (SBQ)false
dc.title.none.fl_str_mv Amazonian biodiversity: a view of drug development for Leishmaniasis and malaria
title Amazonian biodiversity: a view of drug development for Leishmaniasis and malaria
spellingShingle Amazonian biodiversity: a view of drug development for Leishmaniasis and malaria
Calderon,Leonardo de Azevedo
Amazonia
biodiversity
leishmaniasis
Leishmania
malaria
Plasmodium
drug development
title_short Amazonian biodiversity: a view of drug development for Leishmaniasis and malaria
title_full Amazonian biodiversity: a view of drug development for Leishmaniasis and malaria
title_fullStr Amazonian biodiversity: a view of drug development for Leishmaniasis and malaria
title_full_unstemmed Amazonian biodiversity: a view of drug development for Leishmaniasis and malaria
title_sort Amazonian biodiversity: a view of drug development for Leishmaniasis and malaria
author Calderon,Leonardo de Azevedo
author_facet Calderon,Leonardo de Azevedo
Silva-Jardim,Izaltina
Zuliani,Juliana Pavan
Silva,Alexandre de Almeida e
Ciancaglini,Pietro
Silva,Luiz Hildebrando Pereira da
Stábeli,Rodrigo Guerino
author_role author
author2 Silva-Jardim,Izaltina
Zuliani,Juliana Pavan
Silva,Alexandre de Almeida e
Ciancaglini,Pietro
Silva,Luiz Hildebrando Pereira da
Stábeli,Rodrigo Guerino
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Calderon,Leonardo de Azevedo
Silva-Jardim,Izaltina
Zuliani,Juliana Pavan
Silva,Alexandre de Almeida e
Ciancaglini,Pietro
Silva,Luiz Hildebrando Pereira da
Stábeli,Rodrigo Guerino
dc.subject.por.fl_str_mv Amazonia
biodiversity
leishmaniasis
Leishmania
malaria
Plasmodium
drug development
topic Amazonia
biodiversity
leishmaniasis
Leishmania
malaria
Plasmodium
drug development
description Chemotherapy is the only validated therapy for the treatment for the neglected diseases leishmaniasis and malaria. However, the emergence of drug resistance, collateral effects and long-term treatment encourage the development of new and more efficient drugs. The Amazon tropical forest includes the richest areas of biodiversity in the world, including a great number of microbes, plant and animal species that produce a source of interesting biologically active molecules. Several of these molecules, obtained from plant extracts and frog venom have leishmanicidal and plasmodicidal activity, highlighting the potential of this biodiversity for the development of new drugs. In research, modern approaches in new drug development are carried out using combinatorial chemistry, high-throughput screening, bioinformatics, molecular interaction, crystallography and dynamic studies of cellular and systemic toxicity. In Brazil, these techniques are mainly present in only a few academic groups with no efficient connection to industry. The problem associated with over-regulation for accessing the biological material in restricted areas, local populations and indigenous areas places major barriers in the path of research and development of new drugs. Thus, the association of academic research groups in Brazil, encouraged and supported by government and industry, is essential to overcome these major barriers related to the development of new products for treatment of neglected diseases from Amazonian biodiversity in future years.
publishDate 2009
dc.date.none.fl_str_mv 2009-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532009000600003
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532009000600003
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0103-50532009000600003
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Química
publisher.none.fl_str_mv Sociedade Brasileira de Química
dc.source.none.fl_str_mv Journal of the Brazilian Chemical Society v.20 n.6 2009
reponame:Journal of the Brazilian Chemical Society (Online)
instname:Sociedade Brasileira de Química (SBQ)
instacron:SBQ
instname_str Sociedade Brasileira de Química (SBQ)
instacron_str SBQ
institution SBQ
reponame_str Journal of the Brazilian Chemical Society (Online)
collection Journal of the Brazilian Chemical Society (Online)
repository.name.fl_str_mv Journal of the Brazilian Chemical Society (Online) - Sociedade Brasileira de Química (SBQ)
repository.mail.fl_str_mv ||office@jbcs.sbq.org.br
_version_ 1750318169883410432